Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thalassemia | 7 | 2015 | 270 | 0.660 |
Why?
|
Urinary Incontinence, Stress | 7 | 2016 | 181 | 0.650 |
Why?
|
Sample Size | 3 | 2015 | 838 | 0.560 |
Why?
|
Suburethral Slings | 6 | 2016 | 72 | 0.500 |
Why?
|
Hepatitis C, Chronic | 9 | 2011 | 1031 | 0.460 |
Why?
|
Interneurons | 5 | 2023 | 591 | 0.430 |
Why?
|
Survival Analysis | 3 | 2015 | 10112 | 0.380 |
Why?
|
Interferon-alpha | 6 | 2011 | 918 | 0.340 |
Why?
|
Polyethylene Glycols | 6 | 2011 | 1188 | 0.310 |
Why?
|
Biometry | 2 | 2008 | 559 | 0.310 |
Why?
|
Data Interpretation, Statistical | 2 | 2008 | 2690 | 0.300 |
Why?
|
Population Surveillance | 2 | 2008 | 2606 | 0.290 |
Why?
|
Models, Statistical | 4 | 2015 | 5070 | 0.280 |
Why?
|
Antiviral Agents | 9 | 2011 | 3056 | 0.280 |
Why?
|
HIV Infections | 8 | 2024 | 17275 | 0.280 |
Why?
|
Population Dynamics | 1 | 2008 | 307 | 0.270 |
Why?
|
beta-Thalassemia | 3 | 2013 | 235 | 0.260 |
Why?
|
Homosexuality, Male | 3 | 2024 | 1329 | 0.260 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2008 | 706 | 0.220 |
Why?
|
Analgesia, Patient-Controlled | 3 | 2013 | 116 | 0.220 |
Why?
|
Iron Chelating Agents | 3 | 2013 | 138 | 0.220 |
Why?
|
Urologic Surgical Procedures | 2 | 2016 | 309 | 0.210 |
Why?
|
Liver Cirrhosis | 5 | 2011 | 1930 | 0.210 |
Why?
|
Urethra | 2 | 2016 | 406 | 0.210 |
Why?
|
Spironolactone | 3 | 2016 | 410 | 0.210 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2021 | 2197 | 0.210 |
Why?
|
Mass Screening | 2 | 2008 | 5425 | 0.200 |
Why?
|
Schizophrenia | 4 | 2022 | 6913 | 0.190 |
Why?
|
Contact Tracing | 1 | 2003 | 271 | 0.190 |
Why?
|
Blood Group Incompatibility | 2 | 2012 | 135 | 0.180 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1612 | 0.180 |
Why?
|
Rwanda | 4 | 2024 | 659 | 0.170 |
Why?
|
Episode of Care | 1 | 2020 | 127 | 0.170 |
Why?
|
Anemia, Sickle Cell | 3 | 2013 | 1054 | 0.170 |
Why?
|
Neurofibromatosis 1 | 1 | 2024 | 560 | 0.160 |
Why?
|
Artifacts | 1 | 2007 | 1897 | 0.150 |
Why?
|
Papillomaviridae | 2 | 2024 | 1121 | 0.150 |
Why?
|
Ribavirin | 2 | 2010 | 395 | 0.150 |
Why?
|
Algorithms | 2 | 2008 | 13959 | 0.140 |
Why?
|
Urodynamics | 2 | 2016 | 346 | 0.140 |
Why?
|
Hearing Loss | 1 | 2024 | 780 | 0.140 |
Why?
|
Abortion, Induced | 1 | 2022 | 460 | 0.140 |
Why?
|
Erythrocyte Transfusion | 2 | 2012 | 563 | 0.140 |
Why?
|
Physical Therapy Modalities | 1 | 2020 | 536 | 0.140 |
Why?
|
Composite Resins | 1 | 2016 | 69 | 0.130 |
Why?
|
Anti-HIV Agents | 2 | 2023 | 4504 | 0.130 |
Why?
|
Pluripotent Stem Cells | 1 | 2023 | 792 | 0.130 |
Why?
|
Urination | 2 | 2015 | 202 | 0.130 |
Why?
|
Counseling | 1 | 2003 | 1541 | 0.130 |
Why?
|
Dental Restoration, Permanent | 1 | 2016 | 128 | 0.130 |
Why?
|
Program Evaluation | 1 | 2003 | 2490 | 0.120 |
Why?
|
Carcinoma, Hepatocellular | 4 | 2011 | 2292 | 0.120 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 1854 | 0.120 |
Why?
|
North Carolina | 2 | 2007 | 323 | 0.120 |
Why?
|
Cadherins | 1 | 2019 | 898 | 0.120 |
Why?
|
Biostatistics | 1 | 2015 | 164 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2015 | 10146 | 0.110 |
Why?
|
Urinary Bladder, Overactive | 1 | 2015 | 114 | 0.110 |
Why?
|
Stroke Volume | 4 | 2016 | 5460 | 0.110 |
Why?
|
Induced Pluripotent Stem Cells | 3 | 2020 | 1842 | 0.110 |
Why?
|
Hypertension, Pulmonary | 2 | 2015 | 1565 | 0.110 |
Why?
|
Cameroon | 2 | 2024 | 74 | 0.110 |
Why?
|
Siderophores | 1 | 2013 | 61 | 0.110 |
Why?
|
Deferoxamine | 1 | 2013 | 153 | 0.100 |
Why?
|
Pain | 3 | 2013 | 5065 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1401 | 0.100 |
Why?
|
Female | 48 | 2024 | 390316 | 0.100 |
Why?
|
Humans | 63 | 2024 | 758381 | 0.100 |
Why?
|
Phenols | 1 | 2016 | 514 | 0.100 |
Why?
|
Blood Grouping and Crossmatching | 1 | 2012 | 100 | 0.100 |
Why?
|
Hemoglobin SC Disease | 1 | 2011 | 23 | 0.100 |
Why?
|
Low Back Pain | 1 | 2020 | 979 | 0.100 |
Why?
|
Time Factors | 12 | 2020 | 39873 | 0.100 |
Why?
|
Microglia | 1 | 2020 | 1349 | 0.100 |
Why?
|
Adult | 34 | 2024 | 219916 | 0.100 |
Why?
|
Male | 44 | 2024 | 358742 | 0.100 |
Why?
|
Liver Neoplasms | 4 | 2011 | 4313 | 0.100 |
Why?
|
Body Mass Index | 4 | 2024 | 12876 | 0.100 |
Why?
|
Antihypertensive Agents | 1 | 2021 | 2018 | 0.100 |
Why?
|
Penis | 2 | 2024 | 213 | 0.100 |
Why?
|
Anti-Retroviral Agents | 1 | 2021 | 1780 | 0.100 |
Why?
|
Isoantibodies | 2 | 2012 | 661 | 0.100 |
Why?
|
Arginine | 1 | 2015 | 933 | 0.090 |
Why?
|
Middle Aged | 37 | 2024 | 219560 | 0.090 |
Why?
|
Blood Group Antigens | 1 | 2012 | 187 | 0.090 |
Why?
|
gamma-Globins | 1 | 2011 | 96 | 0.090 |
Why?
|
Proportional Hazards Models | 5 | 2023 | 12440 | 0.090 |
Why?
|
Prevalence | 7 | 2024 | 15646 | 0.090 |
Why?
|
Sulfones | 1 | 2013 | 446 | 0.090 |
Why?
|
Irritable Bowel Syndrome | 2 | 2006 | 453 | 0.090 |
Why?
|
Regression Analysis | 2 | 2020 | 6353 | 0.090 |
Why?
|
Stillbirth | 1 | 2013 | 368 | 0.090 |
Why?
|
Heart Failure | 4 | 2016 | 11594 | 0.090 |
Why?
|
Live Birth | 1 | 2013 | 512 | 0.080 |
Why?
|
Narcotics | 1 | 2012 | 336 | 0.080 |
Why?
|
Azacitidine | 1 | 2011 | 334 | 0.080 |
Why?
|
Young Adult | 16 | 2024 | 58808 | 0.080 |
Why?
|
alpha-Thalassemia | 1 | 2009 | 52 | 0.080 |
Why?
|
Quality of Life | 7 | 2016 | 13286 | 0.080 |
Why?
|
Hemoglobins, Abnormal | 1 | 2009 | 119 | 0.080 |
Why?
|
Mitochondria | 2 | 2020 | 3584 | 0.080 |
Why?
|
Benzhydryl Compounds | 1 | 2016 | 900 | 0.080 |
Why?
|
Urinary Incontinence | 1 | 2013 | 495 | 0.080 |
Why?
|
Students, Medical | 1 | 2022 | 1927 | 0.080 |
Why?
|
alpha-Fetoproteins | 1 | 2009 | 222 | 0.080 |
Why?
|
Vasodilator Agents | 1 | 2013 | 973 | 0.080 |
Why?
|
Cluster Analysis | 3 | 2016 | 2697 | 0.080 |
Why?
|
Prefrontal Cortex | 1 | 2019 | 2209 | 0.080 |
Why?
|
Computer Simulation | 2 | 2015 | 6201 | 0.070 |
Why?
|
Health Expenditures | 1 | 2020 | 2348 | 0.070 |
Why?
|
Pyridones | 1 | 2013 | 785 | 0.070 |
Why?
|
Antigens, Viral | 1 | 2011 | 980 | 0.070 |
Why?
|
Collagen | 1 | 2016 | 2635 | 0.070 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2011 | 638 | 0.070 |
Why?
|
Urinary Bladder | 1 | 2013 | 1166 | 0.070 |
Why?
|
Epilepsy | 1 | 2023 | 3269 | 0.070 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2011 | 353 | 0.070 |
Why?
|
Iron | 2 | 2013 | 1786 | 0.070 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1184 | 0.070 |
Why?
|
Hypertension | 2 | 2024 | 8503 | 0.070 |
Why?
|
Recombinant Proteins | 6 | 2011 | 6520 | 0.070 |
Why?
|
Coitus | 1 | 2007 | 132 | 0.070 |
Why?
|
Cholesterol, HDL | 1 | 2013 | 1808 | 0.070 |
Why?
|
Auranofin | 1 | 2005 | 16 | 0.070 |
Why?
|
Malawi | 1 | 2007 | 301 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2013 | 3765 | 0.070 |
Why?
|
Hepatitis B | 1 | 2011 | 701 | 0.060 |
Why?
|
Ventricular Function, Left | 2 | 2016 | 3858 | 0.060 |
Why?
|
Data Collection | 1 | 2015 | 3322 | 0.060 |
Why?
|
Adolescent | 14 | 2024 | 87888 | 0.060 |
Why?
|
Protein Precursors | 1 | 2009 | 1133 | 0.060 |
Why?
|
Condoms | 1 | 2007 | 328 | 0.060 |
Why?
|
Echocardiography, Doppler | 3 | 2015 | 898 | 0.060 |
Why?
|
Disease Progression | 6 | 2011 | 13468 | 0.060 |
Why?
|
Risk Factors | 12 | 2024 | 73806 | 0.060 |
Why?
|
Activities of Daily Living | 1 | 2014 | 2414 | 0.060 |
Why?
|
Cerebral Cortex | 1 | 2020 | 5759 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2015 | 14481 | 0.060 |
Why?
|
Smoking Cessation | 1 | 2016 | 2049 | 0.060 |
Why?
|
Employment | 1 | 2010 | 1112 | 0.060 |
Why?
|
North America | 3 | 2013 | 1276 | 0.060 |
Why?
|
Argentina | 2 | 2016 | 245 | 0.060 |
Why?
|
HIV-1 | 1 | 2021 | 6850 | 0.060 |
Why?
|
Health Promotion | 1 | 2016 | 2202 | 0.060 |
Why?
|
Liver | 4 | 2012 | 7502 | 0.060 |
Why?
|
Audiometry | 1 | 2024 | 253 | 0.060 |
Why?
|
Fatty Liver | 1 | 2009 | 777 | 0.050 |
Why?
|
Educational Status | 1 | 2010 | 2513 | 0.050 |
Why?
|
Sexual Behavior | 2 | 2010 | 2158 | 0.050 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 25953 | 0.050 |
Why?
|
Piperazines | 1 | 2013 | 2511 | 0.050 |
Why?
|
AIDS Serodiagnosis | 1 | 2003 | 220 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5865 | 0.050 |
Why?
|
Vitamin D | 1 | 2016 | 3283 | 0.050 |
Why?
|
Acute Chest Syndrome | 2 | 2012 | 32 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 2 | 2012 | 69 | 0.050 |
Why?
|
Africa, Central | 1 | 2021 | 8 | 0.050 |
Why?
|
Multivariate Analysis | 5 | 2016 | 12096 | 0.050 |
Why?
|
Child, Preschool | 8 | 2024 | 42058 | 0.050 |
Why?
|
Abortion, Legal | 1 | 2022 | 114 | 0.050 |
Why?
|
Sexually Transmitted Diseases | 1 | 2007 | 663 | 0.050 |
Why?
|
Treatment Outcome | 11 | 2016 | 64379 | 0.040 |
Why?
|
Incidence | 4 | 2024 | 21273 | 0.040 |
Why?
|
Anus Diseases | 1 | 2020 | 55 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2013 | 15785 | 0.040 |
Why?
|
Penile Diseases | 1 | 2020 | 45 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 2 | 2021 | 3175 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 12076 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2011 | 2083 | 0.040 |
Why?
|
Child | 11 | 2024 | 79813 | 0.040 |
Why?
|
Intention | 1 | 2022 | 345 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 3975 | 0.040 |
Why?
|
Comorbidity | 3 | 2024 | 10495 | 0.040 |
Why?
|
Follow-Up Studies | 7 | 2016 | 39060 | 0.040 |
Why?
|
Smoking | 1 | 2016 | 9042 | 0.040 |
Why?
|
Patient Dropouts | 1 | 2020 | 412 | 0.040 |
Why?
|
Aging | 2 | 2014 | 8651 | 0.040 |
Why?
|
Aged | 13 | 2021 | 168217 | 0.040 |
Why?
|
Registries | 1 | 2013 | 8176 | 0.040 |
Why?
|
Encephalitis | 1 | 2020 | 438 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2020 | 1339 | 0.030 |
Why?
|
Georgia (Republic) | 1 | 2016 | 39 | 0.030 |
Why?
|
Demography | 1 | 2021 | 1651 | 0.030 |
Why?
|
Valsalva Maneuver | 1 | 2016 | 99 | 0.030 |
Why?
|
United States | 9 | 2016 | 72140 | 0.030 |
Why?
|
Antirheumatic Agents | 1 | 2005 | 1368 | 0.030 |
Why?
|
Blood Transfusion | 2 | 2013 | 1321 | 0.030 |
Why?
|
HIV | 1 | 2023 | 1581 | 0.030 |
Why?
|
Incontinence Pads | 1 | 2015 | 2 | 0.030 |
Why?
|
Signal Transduction | 1 | 2019 | 23341 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14641 | 0.030 |
Why?
|
Russia | 1 | 2016 | 381 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 2569 | 0.030 |
Why?
|
Glutamic Acid | 1 | 2020 | 1167 | 0.030 |
Why?
|
Arginase | 1 | 2015 | 80 | 0.030 |
Why?
|
Research Design | 2 | 2013 | 6154 | 0.030 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2020 | 1132 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2011 | 10171 | 0.030 |
Why?
|
Diagnostic Techniques, Urological | 1 | 2013 | 28 | 0.030 |
Why?
|
Cystoscopy | 1 | 2013 | 133 | 0.030 |
Why?
|
USSR | 1 | 2012 | 19 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2011 | 11894 | 0.030 |
Why?
|
Neurons | 2 | 2023 | 9418 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 243 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2015 | 15638 | 0.030 |
Why?
|
Recovery of Function | 2 | 2013 | 2971 | 0.030 |
Why?
|
Pressure | 1 | 2016 | 1155 | 0.030 |
Why?
|
Prognosis | 4 | 2016 | 29558 | 0.030 |
Why?
|
Mental Processes | 1 | 2014 | 245 | 0.030 |
Why?
|
Lebanon | 1 | 2013 | 245 | 0.030 |
Why?
|
Age Factors | 3 | 2015 | 18357 | 0.030 |
Why?
|
Urban Population | 1 | 2020 | 2023 | 0.030 |
Why?
|
Ontario | 1 | 2013 | 397 | 0.030 |
Why?
|
Life Style | 2 | 2015 | 3886 | 0.030 |
Why?
|
Tetanus Toxin | 1 | 2011 | 46 | 0.020 |
Why?
|
Drug Administration Schedule | 2 | 2010 | 4839 | 0.020 |
Why?
|
Brazil | 1 | 2016 | 1217 | 0.020 |
Why?
|
Erythrocytes | 2 | 2011 | 2413 | 0.020 |
Why?
|
London | 1 | 2012 | 234 | 0.020 |
Why?
|
Hydromorphone | 1 | 2011 | 70 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2012 | 5199 | 0.020 |
Why?
|
Hypercalciuria | 1 | 2011 | 31 | 0.020 |
Why?
|
Blood Urea Nitrogen | 1 | 2011 | 186 | 0.020 |
Why?
|
Candida | 1 | 2011 | 173 | 0.020 |
Why?
|
Office Visits | 1 | 2015 | 596 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2011 | 700 | 0.020 |
Why?
|
Hydroxyurea | 1 | 2012 | 282 | 0.020 |
Why?
|
Iatrogenic Disease | 1 | 2013 | 538 | 0.020 |
Why?
|
Canada | 1 | 2016 | 2111 | 0.020 |
Why?
|
Postoperative Period | 1 | 2015 | 1812 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2016 | 12262 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2011 | 415 | 0.020 |
Why?
|
beta 2-Microglobulin | 1 | 2011 | 328 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2005 | 3755 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2014 | 1570 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2015 | 715 | 0.020 |
Why?
|
Seizures | 1 | 2023 | 2919 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2011 | 677 | 0.020 |
Why?
|
Bilirubin | 1 | 2011 | 437 | 0.020 |
Why?
|
Purines | 1 | 2013 | 605 | 0.020 |
Why?
|
Independent Living | 1 | 2014 | 567 | 0.020 |
Why?
|
Workplace | 1 | 2016 | 857 | 0.020 |
Why?
|
Splenectomy | 1 | 2011 | 391 | 0.020 |
Why?
|
Synapses | 1 | 2019 | 1757 | 0.020 |
Why?
|
Prothrombin | 1 | 2009 | 190 | 0.020 |
Why?
|
India | 1 | 2016 | 2329 | 0.020 |
Why?
|
Pulmonary Edema | 1 | 2012 | 408 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2011 | 604 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2007 | 20052 | 0.020 |
Why?
|
Platelet Count | 1 | 2011 | 775 | 0.020 |
Why?
|
Pilot Projects | 2 | 2013 | 8554 | 0.020 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2013 | 497 | 0.020 |
Why?
|
Spirometry | 1 | 2012 | 923 | 0.020 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2012 | 399 | 0.020 |
Why?
|
Serum Albumin | 1 | 2011 | 673 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 21017 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10747 | 0.020 |
Why?
|
Proteinuria | 1 | 2011 | 594 | 0.020 |
Why?
|
Elephantiasis, Filarial | 1 | 2008 | 31 | 0.020 |
Why?
|
Fluid Therapy | 1 | 2012 | 578 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2013 | 1705 | 0.020 |
Why?
|
Patient Preference | 1 | 2015 | 921 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7583 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2640 | 0.020 |
Why?
|
Morphine | 1 | 2011 | 653 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15396 | 0.020 |
Why?
|
Georgia | 1 | 2007 | 190 | 0.020 |
Why?
|
Albuminuria | 1 | 2011 | 650 | 0.020 |
Why?
|
Prospective Studies | 4 | 2013 | 54136 | 0.020 |
Why?
|
Infant | 2 | 2024 | 36054 | 0.020 |
Why?
|
Postoperative Care | 1 | 2013 | 1471 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 3990 | 0.020 |
Why?
|
Pregnancy | 2 | 2022 | 29742 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2024 | 80170 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2210 | 0.020 |
Why?
|
Physical Examination | 1 | 2012 | 1244 | 0.020 |
Why?
|
Memory Disorders | 1 | 2014 | 1198 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10505 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1338 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5861 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15225 | 0.020 |
Why?
|
Blood Pressure | 1 | 2021 | 8453 | 0.020 |
Why?
|
Drug Utilization | 1 | 2012 | 1187 | 0.020 |
Why?
|
Survival Rate | 2 | 2010 | 12721 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1892 | 0.020 |
Why?
|
Hemoglobins | 1 | 2011 | 1519 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2012 | 2432 | 0.020 |
Why?
|
Cell Line | 1 | 2019 | 15594 | 0.020 |
Why?
|
Long-Term Care | 1 | 2009 | 631 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2015 | 22031 | 0.010 |
Why?
|
Patient Compliance | 1 | 2015 | 2685 | 0.010 |
Why?
|
Cohort Studies | 3 | 2012 | 41252 | 0.010 |
Why?
|
Depression | 2 | 2015 | 8057 | 0.010 |
Why?
|
Sex Distribution | 1 | 2009 | 2283 | 0.010 |
Why?
|
Probability | 1 | 2009 | 2467 | 0.010 |
Why?
|
Mice | 2 | 2022 | 81107 | 0.010 |
Why?
|
Hepacivirus | 1 | 2010 | 1333 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2019 | 14354 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2009 | 2925 | 0.010 |
Why?
|
Age Distribution | 1 | 2009 | 2882 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2013 | 6293 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2011 | 1160 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12604 | 0.010 |
Why?
|
Pain Measurement | 1 | 2013 | 3527 | 0.010 |
Why?
|
Fatigue | 1 | 2010 | 1542 | 0.010 |
Why?
|
RNA, Viral | 1 | 2010 | 2836 | 0.010 |
Why?
|
Autoantibodies | 1 | 2011 | 2118 | 0.010 |
Why?
|
Peripheral Arterial Disease | 1 | 2013 | 1246 | 0.010 |
Why?
|
Universities | 1 | 2007 | 993 | 0.010 |
Why?
|
Viral Load | 1 | 2010 | 3321 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3446 | 0.010 |
Why?
|
Constipation | 1 | 2006 | 561 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2013 | 3586 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2022 | 17768 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2006 | 1673 | 0.010 |
Why?
|
Health Status | 1 | 2013 | 4069 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4244 | 0.010 |
Why?
|
Inpatients | 1 | 2012 | 2551 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13276 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6493 | 0.010 |
Why?
|
Liver Transplantation | 1 | 2011 | 2325 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2012 | 8530 | 0.010 |
Why?
|
Electrocardiography | 1 | 2012 | 6363 | 0.010 |
Why?
|
Abdominal Pain | 1 | 2006 | 1063 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2015 | 58681 | 0.010 |
Why?
|
Obesity | 1 | 2021 | 12870 | 0.010 |
Why?
|
Diarrhea | 1 | 2006 | 1317 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6768 | 0.010 |
Why?
|
Animals | 2 | 2022 | 167777 | 0.010 |
Why?
|
Risk Assessment | 2 | 2010 | 23883 | 0.010 |
Why?
|
Body Weight | 1 | 2009 | 4603 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8426 | 0.010 |
Why?
|
Calcium | 1 | 2011 | 5721 | 0.010 |
Why?
|
Length of Stay | 1 | 2011 | 6439 | 0.010 |
Why?
|
Students | 1 | 2007 | 1734 | 0.010 |
Why?
|
DNA Methylation | 1 | 2011 | 4373 | 0.010 |
Why?
|
Ultrasonography | 1 | 2009 | 5952 | 0.010 |
Why?
|
Databases, Factual | 1 | 2011 | 7980 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2011 | 10417 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2010 | 7817 | 0.010 |
Why?
|
Brain | 1 | 2022 | 26951 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2011 | 11471 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2012 | 36285 | 0.000 |
Why?
|